Browse subjects in this section:
The mission of the California Institute of Technology is to expand human knowledge and benefit society through research integrated with education. We investigate the most challenging, fundamental problems in science and technology in a singularly collegial, interdisciplinary atmosphere, while educating outstanding students to become creative members of society.
PETNET® Pharmaceuticals, Inc., headquartered in Knoxville, Tennessee, is the nation's leading provider of molecular tracers for PET imaging. PETNET® offers the only cyclotron-based nationwide network of radiopharmacies that produce and distribute MetaTrace FDG® and other probes to hospitals, clinics, and provider centers.
Liquidia Technologies provides an enabling material platform: innovative fluoropolymers that are liquids at room temperature, but cure to crystal clear "PTFE-like" elastic solids when exposed to light for a few minutes. The resulting material combines the appealing properties of silicone elastomers and glass – outperforming each, individually – and makes revolutionary applications possible. Liquidia's products will be solvent- and chemically resistant microfluidics and high performance imprint lithographic materials and processes.
The Pacific Northwest Prostate Cancer Research SPORE will involve more than 50 investigators in Seattle and Vancouver, B.C.
The POCRC is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from several research and medical institutions in the region. The broad based approach takes full advantage of the scientific expertise available locally and allows for the pooling of clinical resources, thus facilitating population-based studies despite the low incidence of ovarian cancer
The purpose of the UCLA SPORE in Prostate Cancer is to contribute significantly to progress in the diagnosis, prevention, and treatment of prostate cancer. These goals will be accomplished through multiple and diverse research projects, both in basic science and population-based research, which can be rapidly translated into clinical applications.
Homestead was founded to commercialize a suite of technologies developed at the Institute for Systems Biology (ISB) that have broad utility in the development of novel diagnostic tools. The ISB is a world-renowned non- profit research institute whose mission is to unravel the mysteries of diseases such as cancer, diabetes and AIDS. Homestead will utilize proprietary technologies, licensed from the ISB, to develop diagnostic tools, designed to facilitate early intervention in a variety of diseases.
Materia Incorporated is a leader in developing and commercializing solutions to complex problems in Life Sciences, Polymers and Materials Science, and Chemical Manufacturing. The company practices innovative and proprietary Metathesis and Organocatalysis™ Technologies to provide sustainable cost advantages in the production of small, medium, and large molecules while simultaneously enabling previously unattainable features, qualities, and substances to be obtained.
The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.
Today, UCLA´s Jonsson Comprehensive Cancer Center (JCCC) has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of medical researchers. With a membership of more than 230 physicians and scientists, the Jonsson Cancer Center handles more than 20,000 patient visits per year and conducts hundreds of clinical trials, providing the latest in experimental cancer treatments.
Grab the RSS newsfeed for this category: